Kim Lennart Dueholm
Keine laufenden Positionen mehr
Profil
Kim Lennart Dueholm served as a Director at F-Star Biotechnologische Forschungs-.
Und Entwicklungsges MBH and Novexel SA. He was an Independent Director at Akebia Therapeutics, Inc. in 2014.
He also served as a Director at Neurokey A, Orphazyme A, and ObsEva SA. Prior to that, he worked as a Portfolio Analyst & Principle Scientific Analyst at Novo Nordisk A and as a Partner at Novo Holdings AS (Denmark) and Novo Ventures 1 A from 2000 to 2016.
Dr. Dueholm holds a doctorate degree from the University of Copenhagen and a graduate degree from the University of Southern Denmark.
Ehemalige bekannte Positionen von Kim Lennart Dueholm
| Unternehmen | Position | Ende |
|---|---|---|
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01.04.2016 |
| AKEBIA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.07.2014 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Corporate Officer/Principal | - |
| OBSEVA SA | Direktor/Vorstandsmitglied | - |
Ausbildung von Kim Lennart Dueholm
| University of Southern Denmark | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ORPHAZYME A/S | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| OBSEVA SA | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Finance |
